Hansa Biopharma AB Reports Positive Clinical Results for Imlifidase in Duchenne Muscular Dystrophy Treatment

Hansa Biopharma AB, a biopharmaceutical company based in Lund, Sweden, has announced supportive top-line clinical results from a study involving the use of its immunomodulatory enzyme, imlifidase, in combination with gene therapy for Duchenne muscular dystrophy (DMD) patients. The company, which specializes in treating and preventing rare diseases, has reported these findings on August 4, 2025.

The study involved three DMD patients who were resistant to the gene therapy drug ELEVIDYS from Sarepta. The combination of ELEVIDYS and imlifidase showed early supportive top-line data, indicating a promising approach for patients who do not respond to ELEVIDYS alone. According to the results, after administering imlifidase, the patients experienced a rapid reduction in IgG and anti-AAV antibodies, which facilitated subsequent treatment with ELEVIDYS gene therapy.

Hansa Biopharma’s press release highlighted that the safety profile of imlifidase was consistent with previous experiences, and no new safety signals were reported. This development is significant as it suggests that imlifidase could potentially enhance the efficacy of gene therapies for DMD patients who have developed resistance to treatments like ELEVIDYS.

Market Reaction and Stock Performance

Following the announcement of these positive clinical results, Hansa Biopharma’s stock experienced an uptick. On the same day, the Swedish Stock Exchange saw a general upward trend, with the OMXS30 index rising by 0.5% at the opening of the market. Hansa Biopharma’s shares were among those that increased, reflecting investor optimism about the company’s clinical advancements.

The broader market context also contributed to the positive sentiment, as major European markets, including Frankfurt and Paris, experienced gains. This favorable market environment likely supported the rise in Hansa Biopharma’s stock price.

Company Overview

Hansa Biopharma AB operates exclusively in Sweden and is listed on the Swedish Stock Exchange. The company focuses on developing immunomodulatory enzymes for the treatment and prevention of rare diseases, as well as providing transplant rejection services. With a market capitalization of 2.44 billion SEK and a close price of 29.12 SEK on August 3, 2025, Hansa Biopharma continues to be a key player in the biotechnology sector within the healthcare industry.

For more information, visit Hansa Medical’s official website .

This article provides a concise overview of the recent developments at Hansa Biopharma AB, focusing on the clinical results of imlifidase and its impact on the company’s stock performance.